Molecular subtyping reveals immune alterations in IDH wild‐type lower‐grade diffuse glioma. Issue 3 (15th June 2020)

• Record Type: Journal Article
• Authors: Wu, Fan; Li, Guan‐Zhang; Liu, Han‐Jie; Zhao, Zheng; Chai, Rui‐Chao; Liu, Yu‐Qing; Jiang, Hao‐Yu; Zhai, You; Feng, Yue‐Mei; Li, Ren‐Peng; Zhang, Wei
• Is Part Of: Journal of pathology. Volume 251:Issue 3(2020)
• Page Start: 272
• Page End: 283
• Publication Date: 2020-06-15
• Subjects: IDH wild‐type diffuse LGG -- molecular classification -- immune signature -- prognosis; Pathology -- Periodicals; 616.07
• DOI: 10.1002/path.5468
• Languages: English
• ISSNs: 0022-3417

Abstract

Abstract: Isocitrate dehydrogenase ( IDH ) wild‐type diffuse lower‐grade glioma (LGG) is usually associated with poor outcome, but there have been disputes over its clinical outcome and classification. We present here a robust gene expression‐based molecular classification of IDH wild‐type diffuse LGG into two subtypes with distinct biological and clinical features. A discovery cohort of 49 IDH wild‐type diffuse LGGs from the Chinese Glioma Genome Atlas (CGGA) was subjected to clustering and function analysis. Seventy‐three tumors from The Cancer Genome Atlas (TCGA) were used to validate our findings. Consensus clustering of transcriptional data uncovered concordant classification of two robust and prognostically significant subtypes of IDH wild‐type LGG. Subtype 1, associated with poorer outcomes, was characterized by significantly higher immune and cytolytic scores, M2 macrophages, and up‐regulation of immune exhaustion markers, while Subtype 2, which had elevated lymphocytes and plasma cells, showed relatively favorable survival. Somatic alteration analysis revealed that Subtype 1 showed more frequently deleted regions, such as the locus of CDKN2A / CDKN2B, DMRTA1, C9orf53, and MTAP . Furthermore, we developed and validated a five‐gene signature for better application of this acquired stratification. Our data demonstrate the biological and prognostic heterogeneity within IDH wild‐type diffuse LGGs and deepen our molecular understandi‐g of this tumor entity. © 2020 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.